Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MRI biomarkers of primary CNS lymphoma outcome after MATRix: real world performance.

Frontiers in oncology·2026
Same author

MRI Predictors of Outcome in Primary Central Nervous System Lymphoma Patients Before and After Autologous Stem Cell Transplant.

EJHaem·2026
Same author

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

Blood advances·2026
Same author

Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.

Lancet (London, England)·2026
Same author

Incidence and Survival of Patients With Angioimmunoblastic T-Cell Lymphoma: A Nationwide Population-Based Study Using English Cancer Registration Data.

Hematological oncology·2026

Related Experiment Video

Updated: Jun 12, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Immunotherapy for Epstein-Barr virus-associated malignancies.

Heather M Long1, Gregory Parsonage, Christopher P Fox

  • 1School of Cancer Sciences, University of Birmingham, Birmingham, UK.

Drug News & Perspectives
|June 4, 2010
PubMed
Summary

Epstein-Barr virus (EBV) drives several cancers, but T-cell responses usually control it. T-cell therapy shows promise for EBV-associated malignancies like PTLD and offers a model for other cancers.

More Related Videos

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line
09:14

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Published on: September 28, 2022

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
09:43

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection

Published on: March 30, 2018

Related Experiment Videos

Last Updated: Jun 12, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line
09:14

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Published on: September 28, 2022

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
09:43

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection

Published on: March 30, 2018

Area of Science:

  • Virology
  • Immunology
  • Oncology

Background:

  • Epstein-Barr virus (EBV) is linked to various human cancers, including post-transplant lymphoproliferative disease (PTLD), Hodgkin's lymphoma, and nasopharyngeal carcinoma.
  • A robust virus-specific T-cell response in most adults controls EBV's oncogenic potential, preventing lifelong asymptomatic infections.

Purpose of the Study:

  • To review the efficacy of T-cell therapy in treating EBV-associated malignancies, particularly PTLD.
  • To explore future directions for developing advanced T-cell therapies for other EBV-driven cancers.

Main Methods:

  • Literature review focusing on T-cell therapy outcomes for PTLD.
  • Analysis of recent technological advancements relevant to T-cell therapy development.

Main Results:

  • T-cell therapy has demonstrated impressive results in treating PTLD.
  • EBV-associated cancers serve as a valuable model for broader T-cell-based cancer therapies.

Conclusions:

  • T-cell therapy is a viable and effective treatment for PTLD.
  • Technological progress enhances the potential for developing novel T-cell therapies against various EBV-associated cancers.